دورية أكاديمية
Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies.
| العنوان: | Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies. |
|---|---|
| المؤلفون: | do Rosário Esteves Guimarães C; Post-Graduation Program in Pharmacy, Pharmacy College, Federal University of Bahia, Barão de Geremoabo Street, 147, Ondina, Salvador, Bahia CEP, 40170115, Brazil., de Freitas HF; Post-Graduation Program in Pharmacy, Pharmacy College, Federal University of Bahia, Barão de Geremoabo Street, 147, Ondina, Salvador, Bahia CEP, 40170115, Brazil., Barros TF; Post-Graduation Program in Pharmacy, Pharmacy College, Federal University of Bahia, Barão de Geremoabo Street, 147, Ondina, Salvador, Bahia CEP, 40170115, Brazil. tfbarros@ufba.br. |
| المصدر: | Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] [Braz J Microbiol] 2023 Mar; Vol. 54 (1), pp. 37-52. Date of Electronic Publication: 2022 Dec 28. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Publishing Country of Publication: Brazil NLM ID: 101095924 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4405 (Electronic) Linking ISSN: 15178382 NLM ISO Abbreviation: Braz J Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : Switzerland, AG : Springer International Publishing Original Publication: Rio de Janeiro, RJ, Brasil : Sociedade Brasileira de Microbiologia |
| مواضيع طبية MeSH: | Candida albicans* , Candidiasis*/microbiology, Antifungal Agents/pharmacology ; Proteomics ; Fluconazole/pharmacology ; Biofilms ; Microbial Sensitivity Tests |
| مستخلص: | Biofilms are communities of microbial cells surrounded by an extracellular polysaccharide matrix, recognized as a fungal source for local and systemic infections and less susceptible to antifungal drugs. Thus, treatment of biofilm-related Candida spp. infections with popular antifungals such as fluconazole is limited and species-dependent and alternatively demands the use of expensive and high toxic drugs. In this sense, molecules with antibiofilm activity have been studied but without care regarding the use of important criteria such as antibiofilm concentration lower than antifungal concentration when considering the process of inhibition of formation and concentrations equal to or lower than 300 µM. Therefore, this review tries to gather the most promising molecules regarding the activity against the C. albicans biofilm described in the last 10 years, considering the activity of inhibition and eradication. From January 2011 to July 2021, articles were searched on Scopus, PubMed, and Science Direct, combining the keywords "antibiofilm," "candida albicans," "compound," and "molecule" with AND and OR operators. After 3 phases of selection, 21 articles describing 42 molecules were discussed in the review. Most of them were more promising for the inhibition of biofilm formation, with SM21 (24) being an interesting molecule for presenting inhibitory and eradication activity in biofilms with 24 and 48 h, as well as alizarin (26) and chrysazine (27), with concentrations well below the antifungal concentration. Despite the detection of these molecules and the attempts to determine the mechanisms of action by microscopic analysis and gene expression, no specific target has been determined. Thus, a gap is signaled, requiring further studies such as proteomic analyses to clarify it. (© 2022. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.) |
| References: | Infect Immun. 2007 Apr;75(4):1609-18. (PMID: 17283095) Antimicrob Agents Chemother. 2016 Dec 27;61(1):. (PMID: 27795383) Front Microbiol. 2019 May 14;10:1085. (PMID: 31156594) Annu Rev Microbiol. 2015;69:71-92. (PMID: 26488273) Int J Antimicrob Agents. 2008 Jun;31(6):572-6. (PMID: 18440786) FEMS Yeast Res. 2018 Feb 1;18(1):. (PMID: 29346561) Mycopathologia. 2020 Jun;185(3):415-424. (PMID: 32277380) Sci Rep. 2019 Dec 12;9(1):18941. (PMID: 31831822) Biomed Pharmacother. 2021 Nov;143:112218. (PMID: 34649348) J Mycol Med. 2020 Apr;30(1):100906. (PMID: 31708424) Microbiology (Reading). 2010 Apr;156(Pt 4):1234-1243. (PMID: 20019081) Pharmaceuticals (Basel). 2022 Jan 05;15(1):. (PMID: 35056128) PLoS Pathog. 2006 Jul;2(7):e63. (PMID: 16839200) J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):743-52. (PMID: 25620183) Biochimie. 2016 Feb;121:268-77. (PMID: 26656137) J Mycol Med. 2020 Apr;30(1):100911. (PMID: 32008964) Curr Opin Microbiol. 2019 Dec;52:1-6. (PMID: 31085405) J Fungi (Basel). 2020 Jul 02;6(3):. (PMID: 32630687) Biofouling. 2020 Feb;36(2):126-137. (PMID: 32093497) Rev Peru Med Exp Salud Publica. 2020 Apr-Jun;37(2):276-281. (PMID: 32876217) Int J Antimicrob Agents. 2014 Sep;44(3):269-73. (PMID: 25104135) J Nat Prod. 2015 Dec 24;78(12):2994-3004. (PMID: 26654828) Mycoses. 2018 Oct;61(10):754-763. (PMID: 29893450) BMC Infect Dis. 2017 Jul 10;17(1):481. (PMID: 28693479) Front Med (Lausanne). 2018 Feb 13;5:28. (PMID: 29487851) Nat Rev Microbiol. 2011 Feb;9(2):109-18. (PMID: 21189476) J Cell Biol. 1999 May 17;145(4):757-67. (PMID: 10330404) Front Microbiol. 2020 May 13;11:756. (PMID: 32477284) PLoS One. 2014 Jan 22;9(1):e85836. (PMID: 24465737) Micron. 2012 Feb;43(2-3):497-502. (PMID: 22001373) Pathog Dis. 2016 Jun;74(4):ftw018. (PMID: 26960943) J Med Microbiol. 2018 Jun;67(6):889-892. (PMID: 29717970) J Appl Microbiol. 2021 Apr;130(4):1142-1153. (PMID: 32981148) PLoS Pathog. 2010 Mar 26;6(3):e1000828. (PMID: 20360962) Eur J Med Chem. 2019 Mar 1;165:93-106. (PMID: 30660829) Front Microbiol. 2021 Apr 30;12:638609. (PMID: 33995297) Microbiol Res. 2018 May;210:51-58. (PMID: 29625658) FEMS Microbiol Rev. 2021 May 5;45(3):. (PMID: 33232448) J Antimicrob Chemother. 2012 Mar;67(3):618-21. (PMID: 22167241) Nanomedicine (Lond). 2018 Nov;13(22):2867-2879. (PMID: 30431405) Antimicrob Agents Chemother. 2020 Feb 21;64(3):. (PMID: 31871083) PLoS Pathog. 2012;8(4):e1002585. (PMID: 22496639) NPJ Biofilms Microbiomes. 2019 Aug 23;5(1):21. (PMID: 31452924) Microbiology (Reading). 2011 Nov;157(Pt 11):3232-3242. (PMID: 21903752) Phytomedicine. 2019 Oct;63:153033. (PMID: 31352284) J Control Release. 2014 Oct 28;192:131-40. (PMID: 24997276) Eukaryot Cell. 2005 Apr;4(4):633-8. (PMID: 15821123) Eukaryot Cell. 2004 Aug;3(4):955-65. (PMID: 15302828) Front Cell Infect Microbiol. 2017 Oct 16;7:447. (PMID: 29085811) Molecules. 2019 Nov 14;24(22):. (PMID: 31739552) Microb Biotechnol. 2021 Jul;14(4):1353-1366. (PMID: 33252828) Carbohydr Polym. 2020 Aug 1;241:116254. (PMID: 32507182) Int J Biochem Cell Biol. 2016 Nov;80:1-9. (PMID: 27639679) J Clin Microbiol. 1984 May;19(5):687-93. (PMID: 6429190) Microbiol Spectr. 2015 Aug;3(4):. (PMID: 26350306) J Appl Microbiol. 2021 Jul;131(1):105-123. (PMID: 33226719) Med Mycol. 2018 Aug 1;56(6):653-667. (PMID: 29228383) Crit Rev Microbiol. 2021 Feb;47(1):91-111. (PMID: 33482069) Mol Microbiol. 2019 Jan;111(1):6-16. (PMID: 30299574) Cell Microbiol. 2002 Aug;4(8):461-9. (PMID: 12174081) Mycoses. 2012 May;55(3):199-204. (PMID: 21793943) Prog Lipid Res. 2016 Jan;61:63-72. (PMID: 26703191) Molecules. 2015 Sep 29;20(10):17913-28. (PMID: 26426004) Eur J Med Chem. 2016 Aug 8;118:98-106. (PMID: 27128176) Clin Microbiol Infect. 2018 Jul;24(7):771-777. (PMID: 29133157) J Proteomics. 2019 Sep 30;208:103503. (PMID: 31454558) Future Microbiol. 2013 Oct;8(10):1325-37. (PMID: 24059922) J Infect Chemother. 2018 Sep;24(9):725-728. (PMID: 29773439) Microbes Infect. 2016 May;18(5):310-21. (PMID: 26806384) PLoS One. 2014 May 05;9(5):e93225. (PMID: 24796422) J Fungi (Basel). 2017 Feb 21;3(1):. (PMID: 29371527) J Mycol Med. 2018 Jun;28(2):367-373. (PMID: 29510961) Sci Rep. 2021 Jun 15;11(1):12524. (PMID: 34131212) Bioorg Chem. 2019 Jun;87:209-217. (PMID: 30901676) Mycobiology. 2017 Mar;45(1):25-30. (PMID: 28435351) Clinicoecon Outcomes Res. 2015 Oct 13;7:527-35. (PMID: 26508881) J Fungi (Basel). 2021 Apr 28;7(5):. (PMID: 33924814) Front Cell Infect Microbiol. 2018 Aug 28;8:299. (PMID: 30211127) Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):1797-1819. (PMID: 32372128) J Gen Appl Microbiol. 2020 Jan 31;65(6):277-283. (PMID: 31217414) J Mater Sci Mater Med. 2019 Jun 19;30(7):77. (PMID: 31218489) Trends Microbiol. 2013 Sep;21(9):466-74. (PMID: 23827084) Mol Med Rep. 2019 Apr;19(4):3201-3209. (PMID: 30816484) J Appl Microbiol. 2021 Jul;131(1):11-22. (PMID: 33249681) Eukaryot Cell. 2006 Oct;5(10):1604-10. (PMID: 17030992) |
| فهرسة مساهمة: | Keywords: Activity; Candida albicans; Natural product; Review; Synthetic molecules |
| المشرفين على المادة: | 0 (Antifungal Agents) 8VZV102JFY (Fluconazole) |
| تواريخ الأحداث: | Date Created: 20221228 Date Completed: 20230224 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC9944165 |
| DOI: | 10.1007/s42770-022-00876-1 |
| PMID: | 36576671 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1678-4405 |
|---|---|
| DOI: | 10.1007/s42770-022-00876-1 |